Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 3
2005 17
2006 15
2007 11
2008 13
2009 19
2010 11
2011 11
2012 13
2013 11
2014 23
2015 28
2016 13
2017 2
2018 5
2019 15
2020 19
2021 14
2022 13
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Results by year

Filters applied: . Clear all
Page 1
Depression in cancer: The many biobehavioral pathways driving tumor progression.
Bortolato B, Hyphantis TN, Valpione S, Perini G, Maes M, Morris G, Kubera M, Köhler CA, Fernandes BS, Stubbs B, Pavlidis N, Carvalho AF. Bortolato B, et al. Among authors: pavlidis n. Cancer Treat Rev. 2017 Jan;52:58-70. doi: 10.1016/j.ctrv.2016.11.004. Epub 2016 Nov 16. Cancer Treat Rev. 2017. PMID: 27894012 Review.
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
Live European School of Oncology e-Sessions (e-ESO).
Siano M, Marangoni F, Pavlidis N, Peccatori FA, Aapro M, Eniu A, Rolfo C, Cavalli F, Costa A. Siano M, et al. Among authors: pavlidis n. Crit Rev Oncol Hematol. 2021 Jul;163:103301. doi: 10.1016/j.critrevonc.2021.103301. Epub 2021 Mar 16. Crit Rev Oncol Hematol. 2021. PMID: 33741505 Review.
Sarcoma of unknown primary: myth or reality?
Rassy E, Abou-Jaoude R, Boussios S, Assi T, Kattan J, Khaled H, Pavlidis N. Rassy E, et al. Among authors: pavlidis n. J Egypt Natl Canc Inst. 2022 Jun 27;34(1):27. doi: 10.1186/s43046-022-00128-1. J Egypt Natl Canc Inst. 2022. PMID: 35754068 Review.
Immune checkpoint inhibitors in patients with cancers of unknown primary.
Rassy E, Karam E, Adeleke S, Okoli S, Galante J, Boussios S, Pavlidis N. Rassy E, et al. Among authors: pavlidis n. Eur J Cancer. 2023 Dec;195:113377. doi: 10.1016/j.ejca.2023.113377. Epub 2023 Oct 25. Eur J Cancer. 2023. PMID: 37890352 No abstract available.
Cancer specific risk in multiple sclerosis patients.
Kyritsis AP, Boussios S, Pavlidis N. Kyritsis AP, et al. Among authors: pavlidis n. Crit Rev Oncol Hematol. 2016 Feb;98:29-34. doi: 10.1016/j.critrevonc.2015.10.002. Epub 2015 Oct 9. Crit Rev Oncol Hematol. 2016. PMID: 26481954 Review.
220 results